VVOS
$1.32
Vivos Therapeutics, Inc.
Intraday
Recent News
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of -14.26% and +1.45%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -14.29% and 0.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know
Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ...
Vivos Therapeutics Inc (VVOS) reports a 76% revenue increase in Q3 2025, driven by strategic acquisitions and expanded service offerings.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.56% and +14.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?